Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz
USA
Joined September 2008
- Tweets 7,784
- Following 226
- Followers 124,323
- Likes 2,344
#Breaking: At #ASH25, we’re presenting data across our #hematology portfolio, reinforcing our commitment to addressing remaining unmet needs for people living with hemophilia A, lymphoma and multiple myeloma. Explore our latest research: gene.com/media/press-release…
#Breaking: New positive Phase III data for patients with systemic lupus erythematosus. Learn more: gene.com/media/press-release…
#Breaking: Today we announced positive results from our Phase III study in idiopathic nephrotic syndrome (INS). Learn more: gene.com/media/press-release…
ICYMI: Our medicine to treat lupus nephritis in adults was granted approval by the @US_FDA. Learn more: spr.ly/6019A4AYx
ICYMI: At #ESMO25, our Phase III study showed an investigational, all-oral estrogen blocker combination improved progression-free survival in advanced ER+ breast cancer. Learn more: spr.ly/6016AAnmp
#Breaking: We’re presenting Phase III data showing improved outcomes in muscle-invasive bladder cancer (#MIBC) at #ESMO25. Learn more: gene.com/media/press-release…
#Breaking: The @US_FDA has approved our anti-CD20 monoclonal antibody for the treatment of #LupusNephritis (LN). Read more about how this therapy provides LN patients with more options: gene.com/media/press-release…
#Breaking: At #ESMO25, we’re presenting full Phase III data from our study of an investigational all-oral combination in advanced ER+, HER2- #BreastCancer, post-CDK 4/6 inhibitor and endocrine therapy. Learn more: gene.com/media/press-release…
New Phase III data in uveitic macular edema (UME) at #AAO2025 demonstrate our long-standing commitment to improve care for people with retinal diseases. 📷 Learn about the latest updates in UME: gene.com/media/press-release…
#Breaking: Today, we announced our first Direct-to-Patient (DTP) program for one of our flu treatments to provide Americans with a convenient and affordable way to get the medicine they need to help them stay healthy this flu season. Learn more gene.com/media/press-release…
#Breaking from #ESMO25: We’re presenting new data across our #oncology portfolio, reinforcing our commitment to transformative innovation in some of the most challenging cancers, including breast, bladder, lung and gastrointestinal. Learn more: gene.com/media/press-release…
Breaking: The @US_FDA approved our new treatment regimen for extensive-stage small cell lung cancer (ES-SCLC), where maintenance therapy may help combat the risk of progression. Learn more: gene.com/media/press-release…
#Breaking: At #ECTRIMS2025, we’re presenting new data from our multiple sclerosis portfolio across broad populations, including individuals living with RRMS and PPMS.
Read the press release here: gene.com/media/press-release…
#Breaking: New Phase III data shows a meaningful advancement for people with ER+, HER2- advanced #BreastCancer. Read the release: gene.com/media/press-release…
#Breaking: We presented late-breaking four-year data of our bispecific antibody in people with wet AMD
and Phase IIIb/IV data in PCV, a subtype of this severe eye condition, at #EURETINA2025
➡Read the full details here: gene.com/media/press-release…
#Breaking: Today we announced the decision to initiate a Phase III trial evaluating our investigational RNAi therapy for people with #hypertension, which is informed by Phase II data we presented at #ESC2025. Discover how we are committed to advancing cardiovascular care: gene.com/media/press-release…
Today we broke ground on our new $700M facility in Holly Springs, NC—Genentech’s first East Coast site. This 700K-sq-ft hub will support next-gen metabolic medicines and create 1,900+ jobs, strengthening U.S. innovation in biotech. gene.com/media/press-release…
#Breaking: At #ASRS2025, we’re sharing results from our latest ophthalmology research, including data from our long-term, five-year study in people with wet age-related macular degeneration.
Read the press release here: gene.com/media/press-release…
#Breaking: At AAIC, we’re presenting new data in #Alzheimers, underscoring our commitment to advancing the science in this disease. Learn More: gene.com/media/press-release…
#Breaking: At #18ICML, we’re presenting data from our Phase III trial revealing how our novel combination therapy helped reduce the risk of disease progression for people living with large B-cell #lymphoma (#LBCL) in an outpatient setting. Learn more: gene.com/media/press-release…
